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Abstract
Background: The early stages consecutive to infection of sheep (e.g. primo-infection) by Bovine
leukemia virus mutants are largely unknown. In order to better understand the mechanisms
associated with this period, we aimed at analyzing simultaneously three parameters: B-
lymphocytosis, cell proliferation and viral replication.
Results: Sheep were experimentally infected either with a wild type BLV provirus or with selected
mutants among which: a virus harboring an optimalized LTR promoter with consensus cyclic AMP-
responsive elements, two deletants of the R3 or the G4 accessory genes and a fusion-deficient
transmembrane recombinant. Seroconversion, as revealed by the onset of an anti-viral antibody
response, was detected at 3 to 11 weeks after inoculation. At seroconversion, all sheep exhibited
a marked increase in the numbers of circulating B lymphocytes expressing the CD5 and CD11b
cluster of differentiation markers and, interestingly, this phenomenon occurred independently of
the type of virus. The net increase of the absolute number of B cells was at least partially due to
accelerated proliferation as revealed, after intravenous injection of bromodeoxyuridine, by the
higher proportion of circulating BrdU+ B lymphocytes. BLV proviral DNA was detected by
polymerase chain reaction in the leucocytes of all sheep, as expected. However, at seroconversion,
the proviral loads were lower in sheep infected by the attenuated proviruses despite similar levels
of B cell lymphocytosis.
Conclusions: We conclude that the proviral loads are not directly linked to the extent of B cell
proliferation observed during primo-infection of BLV-infected sheep. We propose a model of
opportunistic replication of the virus supported by a general activation process of B lymphocytes.
Background
Bovine leukemia virus (BLV) is an oncogenic retrovirus
closely related to the primate T-cell leukemia viruses [1].
These viruses are exogenous to their host species [2,3],
have similar genomic organizations [4], integrate into dis-
persed sites within the host genome [5,6] and appear tran-
scriptionally silent in vivo (reviewed by [7]). However,
BLV is unique in the HTLV family of retroviruses because
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it infects and dysregulates B lymphocytes instead of T
cells. The natural host for BLV is cattle but the virus can
also be experimentally transmitted to sheep [8]. The
pathogeneses in these species are globally similar despite
higher frequencies of leukemogenesis in sheep (up to
100%) and shorter latency periods (1–4 years versus 4–10
in cattle) [1]. Following BLV infection, the hosts, either
cattle or sheep, develop a persistent antibody response to
viral proteins and virions can be isolated from ex vivo cul-
tured leucocytes [9]. Detection of antibodies in the
infected animals correlates with a transient B cell lym-
phocytosis [10-13]. In most cases, BLV infection remains
clinically silent, a stage referred to as the asymptomatic or
aleukemic stage of the disease [7]. Only 30% of BLV-
infected cattle develop persistent lymphocytosis (PL), a
polyclonal expansion of B cells coexpressing high levels of
surface IgM, myeloid (CD11b) or T-specific (CD5) mark-
ers [14-16] and less than 5% will die from a fatal leuke-
mia, lymphoma or lymphosarcoma [17].
A major advantage of the BLV system is the possibility to
study viral genetic determinants in relation with infectiv-
ity and pathogenicity in vivo. A strategy, which we previ-
ously described, is based on the use of a cloned BLV
provirus whose sequence can be mutagenized in vitro.
Well characterized mutants can subsequently be injected
into sheep and compared to the wild type virus (WT) [18].
This experimental protocol permitted the correlation of
viral determinants with defined phenotypes in vivo. In
particular, we showed that:
(i) the R3 and G4 accessory genes are required for efficient
viral spread in vivo, although their deletion or mutation
does not hamper infectivity (mutants CRX3 and IG4
described by [1,19,20]).
(ii) restoring a CRE consensus (cyclic-AMP response ele-
ment; TGACGTCA) in the triplicate motif of the imper-
fectly conserved Tax-responsive sequence (TxRE:
AGACGTCA, TGACGGCA, TGACCTCA) increases LTR
promoter activity, as expected, but restricts the proviral
loads in vivo, suggesting that repression of expression is
required for immune escape (CRE mutant; [21]).
(iii) formation of multinucleated syncytia by envelope
dependent cell fusion in vitro is paradoxically not
required for infectivity or efficient viral spread in vivo
(A60V recombinant; [22]).
Importantly, only the A60V envelope mutant behaves as
wild type in terms of infectivity and pathogenesis, in con-
trast to the others (CRX3, IG4 and CRE) therefore referred
to as attenuated. The two categories of viruses, either wild
type (WT and A60V) or attenuated (CRX3, IG4 and CRE)
thus permit to characterize and compare the processes
occurring during primo-infection.
Results
The extent of transient lymphocytosis is similar in sheep 
infected by wild type or mutant proviruses
BLV recombinants with optimized consensus CRE
sequences (CRE clone) and mutants deleted in the R3 and
G4 genes (CRX3 and IG4 proviruses) are impaired in their
ability to propagate efficiently within their host [1,19,21].
The early stages occurring soon after infection by these
mutants and, more particularly, the extent of the transient
B lymphocytosis are however unknown. Therefore, sheep
were infected with well-characterized molecular clones of
BLV proviruses. As control, the hematological parameters
were first determined in uninfected animals, as illustrated
on figure 1A (sheep 4533 BLV-). To this end, PBMCs
(Peripheral Blood Mononuclear Cells) were isolated and
analyzed by flow cytometry for the presence of IgM, CD4
and CD8 markers. Despite some variations in the absolute
numbers of leucocytes, the B (squares), CD4+ (triangles)
and CD8+ (crosses) T cell populations remained remarka-
bly constant over extended periods of time, as expected
(Figure 1A and data not shown for sheep 4534). In con-
trast, a marked increase of the absolute numbers of leuco-
cytes occurred between 2 and 3 weeks post-inoculation of
the wild type BLV provirus (from 6,331 103/ml to 10,262
103/ml, respectively, at days 21 and 28 in sheep 4536
BLV+ WT, Figure 1A; and data not illustrated for animal
n° 4535).
Phenotypic analysis of the sheep n° 4536 PBMCs revealed
that leucocytosis is essentially due to a marked increase in
the B cell numbers (from 2,294 103/ml of blood to 4,858
103/ml, respectively, at days 21 and day 28; see squares),
while the absolute counts of CD4+ (triangles) and CD8+
(crosses) T cells remained relatively constant (as did the γδ
T cell population, data not shown). Furthermore, maxi-
mal B cell accumulation corresponded to the day of sero-
conversion characterized by the onset of an anti-BLV
humoral response (the vertical line at day 28 on Figure
1A).
A similar experiment was performed in parallel with 4
selected BLV mutants (IG4, CRX3, CRE and GP30), the
latter behaving as wild type in terms of pathogenesis and
infectivity in vivo. Interestingly, B cell lymphocytosis
occurred in all sheep independently of the type of provi-
rus (Figure 1B, compare absolute numbers of B cells at day
of seroconversion). A rate of induction was calculated by
dividing the absolute numbers of the B cell population
around seroconversion with those measured at the day of
proviral injection (day 0). This induction rate (repre-
sented in fold increase on Figure 1C) was independent ofRetrovirology 2004, 1:31 http://www.retrovirology.com/content/1/1/31
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Transient B cell lymphocytosis at seroconversion of sheep infected by BLV-mutants Figure 1
Transient B cell lymphocytosis at seroconversion of sheep infected by BLV-mutants. A. Sheep n° 4536 was 
injected with 100 µg of proviral DNA (wild type strain 344 cloned into plasmid pBLV344) whereas animal n° 4533 was used as 
a negative control. At different times post-injection, leucocytes were counted using a Coulter Counter ZN and the total num-
bers of lymphocytes were estimated after examination under a microscope. In parallel, Peripheral Blood Mononuclear Cells 
(PBMCs) were isolated by Percoll gradient centrifugation and the proportions of B, CD4+ T and CD8+ T-cells were determined 
by flow cytometry. The vertical line represents the detection by immunodiffusion of antibodies directed against the virus (day 
28: sheep n° 4536). B. Graphic representation of absolute B cell numbers at viral inoculation (Day 0, yellow bars) and at sero-
conversion (grey bars) of sheep infected by the BLV wild type virus (WT) or mutants (IG4, CRX3, CRE and GP30). The sheep 
coordinates are indicated. C. Fold increase of the B cell population in the infected sheep. The bars correspond to the mean dif-
ference (± standard deviation) between the absolute numbers of B cells at the day of virus inoculation and those determined at 
seroconversion (means of three values).
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the type of provirus, no significant difference being
observed between the wild type and the mutants.
Expression of the CD5 and CD11b cluster of differentia-
tion markers has been associated with BLV-infection,
although B lymphocytes negative for these receptors are
also less efficient targets for the virus [23,24]. Therefore,
we aimed to determine if lymphocytosis detected at the
seroconversion period is preferentially due to an accumu-
lation of B+CD5+ and/or B+CD11b+ cells. For this pur-
pose, PBMCs were dually labeled with an anti-IgM
antiserum together with anti-CD5 or anti-CD11b mono-
clonal antibodies and analyzed by two-color flow cytom-
etry (illustrated on Figure 2A for BLV wild type infected
animal n° 4535: x axis = CD5 or CD11b labeling; y axis =
B labeling). At day 0, two third of the B lymphocytes
expressed CD5 (3,119 in a total of 1,585 + 3,119 B cells)
whereas, at seroconversion, most of them became positive
for this marker (6,906 cells versus 1,273). In parallel, the
number of B+CD11b+ cells also drastically increased
(3,547 cells at day 0 versus 7,526 at the seroconversion
day). Of note, although most B lymphocytes should be
CD5 and CD11b double positive cells, this assumption
could not be formally demonstrated because of cross reac-
tions between two IgG1 isotypes. However, the dot plots
at right on the figure 2A clearly show that the majority of
B cells should express both markers.
In terms of absolute cell counts (i.e. normalized to the cell
numbers per ml of blood), it appeared that B+CD5+ or
B+CD11b+ lymphocytes accumulated at the seroconver-
sion day in wild type infected sheep 4535 and 4536 (com-
pare yellow and shaded bars on the right panels of Figure
2B). This accumulation did not happen in the CD5- or
CD11b-negative B cell populations (left panels) or in neg-
ative controls (uninfected sheep n° 4533 and 4534),
although a relative increase was observed in some infected
animals (particularly 4542 and 4543, Figure 2B, B+CD5-
). Importantly, the net increase of sIgM+CD5+ or
sIgM+CD11b+ populations also occurred in animals
infected by the different mutants independently of the
type of provirus (Figure 2B).
Together, these data demonstrate that primo-infection in
sheep experimentally infected either with a wild type or
mutant BLV proviruses is associated with a transient lym-
phocytosis, extending previous reports [11,12]. At sero-
conversion, all sheep exhibited a marked increase in the
numbers of circulating B lymphocytes expressing for most
of them the CD5 and CD11b cluster of differentiation
markers and, interestingly, this phenomenon occurred
independently of the type of mutant.
Increase of in vivo B cell proliferation during 
seroconversion
In terms of cell dynamics, lymphocytosis is the conse-
quence of a homeostatic deregulation provoked by an
imbalance in the rates of proliferation and/or death. Alter-
natively or concomitantly, the net increase in B lym-
phocyte numbers might be the result of a cell
mobilization between the lymphatic system and the
peripheral blood. We have previously established a proto-
col allowing to quantify these parameters in BLV-infected
sheep [25]. This experimental approach is based on intra-
venous injection of 5-bromo-2'-deoxyuridine (BrdU)
which permits, after its incorporation into DNA, the iden-
tification by flow cytometry of cells that have undergone
proliferation.
In order to label proliferating B lymphocytes during
primo-infection, BrdU was injected weekly over a two
months period and blood was collected at three days after
each injection, a delay required for maximal detection of
labeled cells (see methods) [25]. Figure 3A illustrates an
example of IgM+BrdU+ dual flow cytometry analysis per-
formed at days 0, 24 and 31 after proviral injection into
sheep n° 4536. It appeared that the numbers of B+BrdU+
cells in this sheep increased at day 24 (cell counts of 99 at
day 0 versus 385 at day 24 amongst 10,000 events) and
remained high at day 31 (324 counted events). In
contrast, in sheep n° 4533 used as a negative control, no
variation was observed in terms of absolute numbers (72,
66 and 75 at days 0, 24 and 31) as well as in proportion
of the sIgM-positive cell population (Figure 3B, yellow
bars). In BLV-infected sheep n° 4536, however, this rela-
tive proportion of BrdU-labeled B lymphocytes peaked at
day 24, indicating that these cells underwent proliferation
(black bars on Figure 3B). Interestingly, the burst of
B+BrdU+ cells just preceded the onset of seroconversion
(vertical line at day 28 on Figure 3C) and correlated with
the mid phase of total B lymphocytes counts in the blood.
The most straightforward interpretation is that the net
increase of the B cell population is at least partially due to
proliferation.
Since BLV mutants also induce a transient lymphocytosis,
a kinetics of BrdU incorporation was performed in 4 addi-
tional sheep infected with proviruses IG4, CRX3, CRE and
GP30 (respectively animals n° 4538, 4541, 4543 and
4544; see figure 4). In all sheep, the high absolute num-
bers of B lymphocytes (squares) observed at seroconver-
sion (vertical line) was preceded by a net increase in the
BrdU positive population (lozenges).
Together these data demonstrate that transient lymphocy-
tosis occurring in BLV infected-sheep is at least partially
due to an increase in cell proliferation as assessed by BrdURetrovirology 2004, 1:31 http://www.retrovirology.com/content/1/1/31
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The lymphocytosis is due to an accumulation of B lymphocytes expressing CD5 and /or CD11b Figure 2
The lymphocytosis is due to an accumulation of B lymphocytes expressing CD5 and /or CD11b. A. PBMCs were 
isolated from BLV wild type infected sheep (n° 4535) and labeled with anti-sIgM 1H4 monoclonal in combination with CD5 or 
CD11b antibodies. Ten thousand cells analyzed by flow cytometry are represented as dot plots (Y axis = B cells; X axis = CD5 
or CD11b expressing cells). Illustrated data correspond to the dot plots performed at day 0 (provirus injection) and at the 
seroconversion day. The total numbers of B cells are indicated in the upper quadrants. B. Histogram representation of the 
absolute numbers of B cells expressing (right panels) or not (left panels) CD5 or CD11b in sheep infected with wild type 
viruses (n° 4535 and 4536), or mutants (pBLVIG4 in n° 4537 / 4538, pBLVCRX3 in n° 4539 / 4541, pBLVCRE3X in n° 4542 / 
4543, pBLVA60V in n° 4544 / 4545). Sheep n° 4533 and 4534 were used as uninfected controls. * represents the absolute 
number of cells at day 24 of the experiment.
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The lymphocytosis correlates with increased B cell proliferation at seroconversion Figure 3
The lymphocytosis correlates with increased B cell proliferation at seroconversion. Once per week over a 2 
months period, 500 mg of bromodeoxyuridine (BrdU) were injected intravenously into BLV-infected (n° 4536) and control (n° 
4533) sheep. An aliquot of blood (1 ml) was collected at three days post-BrdU injection. After lysis of the red blood cells, B 
lymphocytes were labeled with an anti-sIgM antibody. Next, cells were stained with anti-BrdU FITC in the presence of DNase 
and analyzed by two-color flow cytometry. A. Dot Plot graphs of B lymphocytes (Y axis) labeled in combination with BrdU (X 
axis) in uninfected control animal (n° 4533) and in a BLV wild type infected sheep (n° 4536) performed at days 0, 24 and 31. 
Day 31 corresponds to the first data obtained just after seroconversion of sheep n° 4536. Ten thousand events were acquired 
by flow cytometry and PBMCs were selected by the FSC/SSC gating method. The total numbers of B cells are indicated in the 
upper quadrants. B. Histogram of the proportions of BrdU+ labeled B cells (in % of the total B lymphocyte population). C. 
Graphic representation of the proportions of B+BrdU+ cells within the total B lymphocyte population (at days 3 and 7 post-
injection) and the corresponding absolute numbers of B lymphocytes observed during the experiment. The BrdU was injected 
at days 14, 21, 28, 35, 42 and 52. The vertical line represents the detection of the seroconversion day.
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In vivo B lymphocyte proliferation in sheep infected with BLV mutant proviruses Figure 4
In vivo B lymphocyte proliferation in sheep infected with BLV mutant proviruses. Graphic representation of the 
proportions of B+ BrdU+ cells within the total B lymphocyte population (at days 3 and 7 post-injection) and the corresponding 
absolute numbers of B lymphocytes in sheep (n° 4538, 4541, 4543 and 4544) infected, respectively, with BLV mutants (IG4, 
CRX3, CRE and GP30). The BrdU was injected at days 14, 21, 28, 35, 42 and 52. The vertical line corresponds to the serocon-
version day as determined by an immunodiffusion test.
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incorporation and, surprisingly, this phenomenon
occurred independently of the type of virus.
Lymphocytosis and B cell proliferation are independent of 
the proviral loads
With the aim to quantify the proviral loads, viral DNA lev-
els within the circulating blood of all sheep were deter-
mined by semiquantitative PCR. The genomic DNAs were
extracted from blood samples collected at seroconversion
and the sequences corresponding to the viral tax  gene
were amplified by PCR. The number of PCR cycles was
adapted in order to compare the relative amounts of pro-
viral sequences in the blood samples. The amplicons were
then analyzed by Southern Blotting using a BLV tax probe.
Amplification of the gapdh gene was used as internal con-
trol for chromosomal DNA integrity (Figure 5A). As con-
trols for PCR contaminations, no signal was generated in
DNA samples from uninfected sheep at day 0 (n° 4533
and 4534). In contrast, PCR amplification of the tax gene
using the genomic DNA from WT infected sheep (sheep
n° 4535 an 4536) yielded a 1 kb fragment as expected.
Under similar conditions, a weaker signal was generated
by amplification of genomic DNA isolated from animals
infected by mutant proviruses (Figure 5A). Phosphorim-
ager quantification of these hybridization signals revealed
that mutants IG4, CRX3 and CRE replicated at lower pro-
viral loads compared to the wild type or the non-attenu-
ated GP30 viruses (Figure 5B). Using real-time PCR
performed as described by [26], the proviral loads were
estimated to be 270 and 245 copies per 1,000 cells in
sheep infected, respectively, with the wild type virus and
the GP30 recombinant whereas the levels yielded by the
other mutants were significantly reduced (27, 40 and 24
copies / 1,000 cells for IG4, CRX3 and CRE, respectively)
(Figure 5B).
Together these data show that, around the seroconversion
period, the proviral loads are reduced in sheep infected by
attenuated mutants.
Conclusions
We have studied here the interplay between the efficiency
of viral spread, the cellular proliferation within the host
and the extent of cell accumulation during the period con-
secutive to the infection of sheep by bovine leukemia
virus. We compared two categories of viruses based on
their ability to infect and expand within their host: those
behaving as wild type (WT and GP30) or so-called atten-
uated mutants (IG4, CRX3 and CRE). Experimental infec-
tion of sheep with these two types of viruses led to a
surprising observation, namely, a similar extent of tran-
sient lymphocytosis independently of the proviral loads
(see Figure 6). In other words, the total B lymphocyte
accumulation within the peripheral blood is not modu-
lated by the amount of viral copies. Another contribution
of this report is the demonstration that transient lym-
phocytosis arising just prior to seroconversion is at least
partially due to an increase in B cell proliferation (Figure
6). In fact, since lymphocytes rest within the peripheral
blood in the G0/G1 phase of the cell cycle (unpublished
data), proliferation occurs in other sites i.e. the bone mar-
row, spleen, lymph nodes and Peyer's Patches. Therefore,
the accumulation of BrdU+ B lymphocytes might also be
the consequence of an increased outflow from these
sources estimated, in non-infected sheep, at 30 × 106 cells
per gram of lymph node in one hour [27]. Conversely,
impaired recirculation to the lymphatic system would
also create an imbalance in the B lymphocyte counts (1 g
of lymph node receives 1.2 × 108 cells per hour [27]).
Answering to this question would require canulation of
lymph nodes allowing the precise quantification of the
cellular flows.
With the aim to correlate lymphocytosis with a defined B
cell sub-population, we have demonstrated that two sur-
face molecules, CD5 and CD11b, whose expression has
been previously associated with late stages of BLV infec-
tion [13-15,23,24] are also important markers at the sero-
conversion period. In human and mice, the B
lymphocytes expressing the CD5 and CD11b proteins are
referred to as B-1a cells. B lymphocytes that are CD5- and
CD11b+ are called B-1b and have a similar function than
the B-1a subset [28]. Compared to the conventional B-2
cells (e.g. CD5- CD11b-), the B-1 population exhibits dif-
ferent developmental schemes, phenotypes, antibody rep-
ertoires, localization and behaviors. In humans, elevated
numbers of B-1 cells have been reported in patients with
Sjorgen's syndrome, rheumatoid arthritis, chronic lym-
phocytic leukemia and AIDS [29-32]. In mice, increased
numbers of B-1 cells have been observed in a number of
naturally occurring and genetically manipulated strains
that develop autoimmune manifestations [33]. B-1 cells
are believed to be the major source of natural IgM, a poly-
reactive and weakly autoreactive antibody, which is pro-
duced in the absence of exogenous antigenic stimulation
[34]. Consistent with this model, IgM specificities within
the B-1 repertoire include phosphorylcholine, phosphati-
dylcholine, thymocytes, lipopolysaccharide and influenza
virus [33]. Interestingly, in sheep, the B-1 population also
expands in response to infection with other pathogens
like Trypanosoma evansi and Pasteurella haemolytica [35,36].
In this context, we speculate about an opportunistic
mechanism of BLV replication supported by a general acti-
vation of B-1a lymphocyte proliferation, which could thus
be a primary B-cell humoral response. Successive divi-
sions of B-1a cells would thereby expand the number of
potential targets for the virus. During this period, the abil-
ity of the virus to colonize new cells would be crucial, a
fact that is reflected by the differential proviral loads
between the wild type and attenuated viruses.Retrovirology 2004, 1:31 http://www.retrovirology.com/content/1/1/31
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Reduced proviral loads at seroconversion in sheep infected with attenuated mutants Figure 5
Reduced proviral loads at seroconversion in sheep infected with attenuated mutants. A. At seroconversion day, 
DNA was extracted from blood isolated from wild type or mutant-infected sheep, as indicated. Proviral sequences were ampli-
fied by 25 cycles of PCR using tax specific primers. The amplification products were resolved on a 1% agarose gel and analyzed 
by Southern blotting with a BLV tax probe. Blood samples from uninfected sheep n° 4533 and 4534 were used as controls for 
PCR contamination. A PCR amplification of the gapdh gene was used as an internal control for DNA integrity. B. Mean proviral 
loads at seroconversion. For each category of mutant-infected sheep, the mean values of the proviral loads (in arbitrary units ± 
standard deviations as determined after Phosphorimaging scanning) were statistically compared using the Student t test to the 
mean proviral load of the wild type group (WT). The data result from three independent experiments using DNAs extracted 
around the seroconversion period (NS: p > 0.05 non-significance; * 0.01 < p < 0.05; *** p < 0.001, Student t test). Using real-
time PCR, the proviral loads were estimated to be 270 and 245 copies per 1,000 cells in sheep infected, respectively, with the 
wild type virus and the GP30 recombinant whereas the levels yielded by the other mutants were significantly reduced (27, 40 
and 24 copies / 1,000 cells for IG4, CRX3 and CRE, respectively).
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Differences in the infectious potential of the attenuated
viruses are the consequence of mutations in accessory
genes (R3 and G4) or in the LTR promoter (CRE) [19,21].
Although the role of R3 is still unknown, its homologue
expressed by HTLV-1 (p12) interacts with the IL-2 recep-
tor as well as with calcineurin and is crucial during the ini-
tial steps of infection [37-39]. BLV G4 and HTLV-1 p13
bind to the same cellular protein, farnesyl pyrophosphate
synthetase [40] but modulate differentially cell transfor-
mation in vitro [20,41]. The defect in BLV propagation
associated with the CRE mutant relates to its inability to
repress basal expression [21]. Optimization of the imper-
fect CRE enhancer sequences present in the LTR creates a
more efficient promoter, as expected, but restricts the pro-
viral loads indicating that transcriptional silencing is
required for viral persistence and spread. The reduced
capacity of the CRE, G4 and R3 mutants to propagate are
thus caused by different genetic defects and data presented
in this report further extent our previous observations
[1,19,21]. More surprisingly is the replication efficiency
exhibited by the GP30 envelope mutant. Unable to
induce membrane fusion, at least as measured by classical
syncytia formation tests, the GP30 virus propagates at
wild type levels [22]. Besides a possible experimental
caveat based on the lack of sensitivity of the syncytium
assay in vitro, our previous (and most straightforward)
hypothesis postulated that viral spread mainly occurred
via clonal expansion of the infected lymphocytes with few
or non-limiting cell-to-cell transmissions. Figure 5 dem-
onstrates that the proviral loads of the GP30 mutant are at
Schematized summary of proliferation rates, proviral loads and lymphocytosis associated with primo-infection Figure 6
Schematized summary of proliferation rates, proviral loads and lymphocytosis associated with primo-infec-
tion. Sheep, which were experimentally infected with BLV wild type or mutant proviruses (virus inoculation), exhibited a simi-
lar extent of transient accumulation of B-lymphocytes (—). This transient lymphocytosis arising just before seroconversion is 
at least partially due to an increase in B cell proliferation (peak of B cell proliferation •••••). In contrast, the proviral loads 
greatly differ among the two categories of sheep, e.g. infected with wild type (- - -) or attenuated viruses (— ••).
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wild type levels even during the early steps of infection, a
period thought to be associated with active infection of
novel cells. Preliminary inverse PCR amplification data
indicate that the number of target cells carrying integrated
GP30 or wild type proviruses are not significantly differ-
ent (F. Mortreux, ongoing work). We thus have to recon-
sider our interpretation and propose that the syncytium
assay does not reflect the infectious potential in vivo. In
terms of its biological properties in sheep, the GP30
recombinant should thus be considered as, or close to,
wild type at least during primo-infection.
In conclusion, we have characterized here the initial steps
consecutive to BLV infection of sheep. We show that this
period is characterized by a transient accumulation of
CD5+ / CD11b+ B lymphocytes resulting, at least in part,
from increased proliferation. Furthermore, the extent of B
cell lymphocytosis is not directly linked to the proviral
loads reached by the wild type and mutant viruses. On
basis of a comparative leukemia approach, these results
could be informative for the related human T-lympho-
tropic viruses.
Methods
Experimental animals
Twelve sheep of one year old were kept under controlled
conditions at the Veterinary and Agrochemical Research
Centre (Machelen, Belgium). Two animals (n° 4533 and
4534) were used as uninfected controls whereas sheep n°
4535 and 4536 were experimentally infected with a BLV
wild type cloned provirus (strain 344) [18]. Briefly, 100
µg of plasmid DNA were mixed with 200 µl of N-[1-(2,3
dioleoloxyl)propyl]-N,N,N-trimethylammonium methyl-
sulfate (DOTAP; Roche Diagnostics) in 1 ml of HBS (20
mM HEPES-150 mM NaCl, [pH 7.4]) and injected intra-
dermally into the back of each sheep. Plasmids containing
the mutant proviruses pBLVIG4 (harboring a stop codon
in the G4 open reading frame; [19], pBLVCRX3 (deleted
in R3; [1]), pBLVCRE3X (in which the CRE imperfect
sequences were mutated to TGACGTCA; [21]) and
pBLVA60V (alanine codon 60 of the GP30 transmem-
brane gene being mutated into valine; [22]) were injected,
respectively, in sheep n° 4537 / 4538, n° 4539 / 4541, n°
4542 / 4543 and n° 4544 / 4545. Twice a week, the total
leukocyte counts were determined by using a Coulter
counter ZN, and the number of lymphocytes was esti-
mated after examination under the microscope after stain-
ing with May-Grunwald Giemsa. In parallel, the sera from
each sheep were analyzed for BLV seropositivity using
immunodiffusion and enzyme-linked immunosorbent
assay (ELISA) techniques [42].
Immunophenotyping of sheep
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by Percoll gradient centrifugation and their viability
was estimated by trypan blue dye exclusion [43]). PBMCs
were labeled with monoclonal antibodies (Mabs) directed
against surface immunoglobulin M (anti-sIgMs, clone
1H4, mouse IgG1; Pig45A2, mouse IgG2b), CD4 (ST4,
mouse IgG1), CD5 (CC17, mouse IgG1), CD8 (CC58,
mouse IgG1) and CD11b (CC125, mouse IgG1) provided
by C. Howard (Institute for Animal Health, Compton,
United Kingdom) and by I. Schwartz-Cornil (INRA, Jouy-
en-Josas, France) or obtained from VMRD Inc. Cells were
then labeled with a rat anti-mouse IgG1 phycoerythrin
(PE)-antibody (Becton Dickinson Immunocytometry Systems)
or with a goat anti-mouse IgG2b fluorescein
isothiocyanate (FITC)-conjugate (Caltag Laboratories).
Finally, PBMCs were analyzed by flow cytometry on a Bec-
ton Dickinson FACScan flow cytometer. Ten thousand
events were collected for each sample and data were ana-
lyzed with the Cellquest software (Becton Dickinson Immu-
nocytometry Systems).
Analysis of 5-bromo-2'-deoxyuridine in vivo
Each week during two months, sheep were injected intra-
venously with 500 mg of 5-bromo-2'-deoxyuridine (Sigma
Aldrich) resuspended in physiologic serum (NaCl 0.9%).
To evaluate BrdU-incorporation, blood was collected at
three and seven days after each BrdU injection. The red
blood cells were lysed with 1× FACS Lysing Solution (Becton
Dickinson Immunocytometry Systems), the leucocytes were
washed twice with PBS containing 0.5% Bovine Serum
Albumin (BSA) (Sigma Aldrich) and incubated in the pres-
ence of biotinylated 1H4 monoclonal antibody for 30
min at 4°C. Next, the cells were labeled with streptavidin-
phycoerythrin (Becton Dickinson Immunocytometry Systems)
and incubated with 1× FACS Permeabilizing Solution (Bec-
ton Dickinson Immunocytometry Systems). Finally, leuco-
cytes were stained with anti-BrdU FITC antibody in the
presence of DNase (Becton Dickinson Immunocytometry
Systems) and analyzed by flow cytometry.
Semiquantitative PCR analysis
DNA isolations were performed directly on blood using
the Wizard®Genomic DNA Purification Kit (Promega). An
aliquot of 300 µl of blood were mixed with 900 µl of Cell
Lysis Solution and incubated for 10 minutes at room tem-
perature. After two washes with the same buffer, the cells
were resuspended in 300 µl of Nuclei Lysis Solution and
incubated for one hour at 37°C. Then, the samples were
digested during 15 minutes at 37°C in the presence of 1.5
µl of RNase Solution. Proteins were precipitated by adding
100  µl of Protein Precipitation Solution to the nuclear
lysates. After centrifugation at 13,000 g, the supernatant
was mixed with an equal volume of isopropanol, centri-
fuged and ethanol precipitated. Five hundred nanograms
of the purified DNAs were amplified in the presence of
200 µM of deoxynucleotides, 2.5 U of Taq DNA polymer-
ase, and 200 ng of primers. The primers used (PCRTA 5'-Retrovirology 2004, 1:31 http://www.retrovirology.com/content/1/1/31
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CTCTTCGGGATCCATTACCTGA-3' and PCRTC 5'-CCT-
GCATGATCTTTCATACAAAT-3') encompass the region
from position 7999 to 6990 of the BLV tax gene [44]. In
parallel, the primers G3PDHA (5'-CATGTGGGCCAT-
GAGGTCCACCAC-3') and G3PDHS (5'-GACCCCT-
TCATTGACCTCAACTACA-3') were used to amplify the
gapdh  gene. The samples were denatured for 5 min at
94°C, and amplified by 25 cycles of PCR (30 s at 94°C, 30
s at 57°C, and 1 min at 72°C). After a final elongation
step of 10 min at 72°C, 20 µl of the amplification prod-
ucts were resolved on a 1% agarose gel, transferred to a
Hybond N+ membrane (Amersham Pharmacia Biosciences),
and hybridized either with a BLV tax (a 1-kb ClaI insert
from plasmid pGEM7zfLOR1) or with a gapdh  probe
labeled with α-32P dCTP. Quantification of 32P signal was
performed using a PhosphorImager  (Personal Molecular
Imager FX System,Biorad).
Real-time PCR was performed using 6FAM-labeled MGB
probes specific for the BLV pol gene and the 18S ribosomal
DNA sequences essentially as described in reference [26].
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